glp·helper
glphelper.com/semaglutide/north-carolina/apex
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Apex, NC

Verified Semaglutide providers in Apex, NC. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
28
as of today
§ 02Provider directory: North Carolina
28 of 28 shown

Find a Semaglutide provider in North Carolina.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by North Carolina city · /semaglutide/north-carolina/{city}
§ 03Getting Semaglutide in Apex
28 providers · Apex, NC

How to get Semaglutide in Apex.

28 GLP-1 prescribers and 6 local resource types are on record for Apex, plus 3 nearby towns in the directory.

Prescribers in Apex
28 prescribers
28 GLP-1 prescribers in Apex, most listed as Family Medicine (13), Internal Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). Any North Carolina-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Cary (29 providers), Garner (27 providers) and Raleigh (40 providers).
Around the prescription in Apex
6 listed nearby
47 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Apex.
Medicaid (weight loss)
Covered
As of April 2026, North Carolina Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Apex

Apex, North Carolina has a population of 58,780 people. The adult obesity rate in Apex is an age-adjusted estimate of 25.6%, 8.9 percentage points below the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 7.5% of adults in Apex. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 14.8% of adults in Apex.

of Apex adults have obesity
25.6%
diagnosed diabetes
7.5%
no regular physical activity
14.8%

Age-adjusted estimates for Apex, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshow tirzepatide titration works
§ 05Support around Semaglutide in Apex
6 dietitians

The prescription is one part. Here is the rest, in Apex.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Apex, NC, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Sandra Allen, RD, LDN
RD
Registered dietitian
508 Fulton St
Call 919-286-0411NPI 1144289091
Linda Andreani, RD
RD
Registered dietitian
1307 Grappenhall Dr
Call 516-458-5197NPI 1609700970
Meredith Arangala, RD, LDN, CNSC
RD
Registered dietitian
40 Duke Medicine Circle
Call 919-684-2110NPI 1306571047
Jessica Arner, RD, LDN, CFNIP
RD
Registered dietitian
3904 Rustic Mill Dr
Call 919-623-0063NPI 1689451163
Heba Ashter
RD
Registered dietitian · Metabolic
2229 Chattering Lory Ln
Call 919-785-6470NPI 1144154394
Megan Bereman, RD LDN
RD
Registered dietitian
Student Health Services
Call 919-513-1578NPI 1760654057

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Onelife Fitness - Apex
GYM
4.4 on Google · 327 reviews
1441 Beaver Creek Commons Dr
Website
Fit For Life 24
GYM
4.4 on Google · 254 reviews
814 Perry Rd
Website
Life Time
GYM
4.1 on Google · 191 reviews
1040 Vision Dr
Website
F45 Training West Apex
GYM
5.0 on Google · 124 reviews
1756 Olive Chapel Rd
Website
Iron Lair
GYM
5.0 on Google · 119 reviews
2501 Schieffelin Rd Ste 124
Website
Rock Solid Warrior - South Apex
GYM
5.0 on Google · 114 reviews
2131 E Williams St Ste 106
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in North Carolina

NPI-verified Semaglutide (semaglutide) prescribers and clinics, never ranked by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in North Carolina

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]